Lannett gains generic product portfolio from Endo subsidiary
09-05-2018
Amneal and Impax merge to become ‘fifth largest’ generics company
19-10-2017
ericsphotography / iStockphoto.com
A judge has found it unlikely that Impax Laboratories would launch a generic drug before a final court decision in related patent litigation and has dismissed a case against the company.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Federal Trade Commissin, FTC, D Michael Chappell, patent, Endo Pharmaceuticals, Opana ER, Impax Laboratories
